Pulmonary Rehabilitation in Patients With Sarcoidosis

NCT02044939 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-04-07

No results posted yet for this study

Summary

The primary objective of the study is to assess the improvement of daily activity in subjects with Stage IV Pulmonary Sarcoidosis one year after the conduct of a pulmonary rehabilitation program.

The secondary objectives are the following:

* assess the improvement of daily activity at several times : 2, 6 and 12 months after the beginning of a pulmonary rehabilitation program
* assess the improvement of exercise capacity by tests used in medical practice
* assess the correlation between daily activity and exercise capacity
* assess the improvement of dyspnea
* assess the improvement of quality of life and psychological state

Conditions

  • Stage 4 Pulmonary Sarcoidosis

Interventions

OTHER

Pulmonary rehabilitation program

Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Benoît WALLAERT, MD PhD · Clinique des Maladies Respiratoires, CHRU de Lille

  • Frédéric BART, MD · Service de Pneumologie, CH Béthune

  • Dominique VALEYRE, MD PhD · Service de pneumologie, Hôpital Avicenne AP-HP

  • Dominique ISRAEL-BIET, MD PhD · Service de Pneumologie, Hôpital européen Georges Pompidou. AP-HP

  • Jean AMOURETTE, MD · Service de Pneumologie, CH Arras

  • Yves PACHECO, MD PhD · Centre Hospitalier Lyon Sud

  • Vincent COTTIN, MD PhD · Service de Pneumologie, Hôpital Louis Pradel, Lyon

  • Martine REYNAUD-GAUBERT, MD PhD · CHU Nord, APHM Marseille

  • Sylvie LEROY, MD · Service de Pneumologie, Hôpital Pasteur - Pavillon H, CHU de Nice

  • Gaëtan DESLEE, MD · Hôpital Maison Blanche, CHU de Reims

  • François STEENHOUWER, MD · Service de Pneumologie, Hôpital Victor Provo, Roubaix

  • Alain DIDIER, MD · Clinique des Voies Respiratoires, Hôpital Larrey, Toulouse

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-10
Primary Completion
2017-07-06
Completion
2017-07-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044939 on ClinicalTrials.gov